Document is current

Any future updates will be listed below

Peptide-Tetrahydroisoquinoline (THIQ) Conjugated Derivatives as Dual-Targeting Therapeutics: Superior VEGFR-2 Inhibition and Antioxidant Activity against Renal Cell Carcinoma

Crossref DOI link: https://doi.org/10.1007/s10989-025-10765-4

Published Online: 2025-10-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark